Syros Pharmaceuticals Management

Management criteria checks 2/4

Syros Pharmaceuticals' CEO is Conley Chee, appointed in Dec 2023, has a tenure of less than a year. directly owns 0.084% of the company’s shares, worth $115.45K. The average tenure of the management team and the board of directors is 2.1 years and 11.1 years respectively.

Key information

Conley Chee

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.08%
Management average tenure	2.1yrs
Board average tenure	11.1yrs

Recent management updates

Recent updates

CEO

Conley Chee (53 yo)

less than a year

Tenure

Mr. Conley Chee serves as President, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc. since December 02, 203. He served as Chief Commercial Officer at Syros Pharmaceuticals, Inc. since Sep...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Richard Young	Scientific Founder	no data	US$239.66k	0.15% $ 199.2k
David Roth	Chief Medical Officer	8.4yrs	US$1.76m	0% $ 0
Conley Chee	CEO, President & Director	less than a year	no data	0.084% $ 115.5k
James Bradner	Founder	no data	no data	no data
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	no data	no data	no data
Jason Haas	Chief Financial Officer	2.6yrs	US$2.82m	0.092% $ 126.0k
Karen Hunady	Director of Corporate Communications & Investor Relations	no data	no data	no data
Gerald Quirk	Chief Legal Officer & Head of Business Development	1.6yrs	US$1.46m	0.15% $ 203.9k
Lisa Roberts	Vice President of Human Resources	1.3yrs	no data	no data
Kristin Stephens	Chief Development Officer	3.9yrs	no data	0.094% $ 129.5k

2.1yrs

Average Tenure

55yo

Average Age

Experienced Management: 0LC7's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Richard Young	Scientific Founder	12.5yrs	US$239.66k	0.15% $ 199.2k
Conley Chee	CEO, President & Director	less than a year	no data	0.084% $ 115.5k
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	11.1yrs	no data	no data
Peter Karl Wirth	Independent Chairman	7.3yrs	US$211.28k	0.045% $ 61.6k
Mark Murcko	Member of Scientific Advisory Board	11.1yrs	no data	no data
Andrew Oh	Independent Director	1.7yrs	US$135.67k	0.045% $ 61.6k
Nancy Simonian	Director	11.1yrs	US$3.49m	0.55% $ 757.5k
Gerard Evan	Member of Scientific Advisory Board	11.1yrs	no data	no data
Scott Biller	Member of Scientific Advisory Board	11.1yrs	no data	no data
Bradley Bernstein	Member of Scientific Advisory Board	no data	no data	no data
Stefan Knapp	Member of Scientific Advisory Board	11.1yrs	no data	no data
Aviv Regev	Member of Scientific Advisory Board	11.1yrs	no data	no data

11.1yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 0LC7's board of directors are seasoned and experienced ( 11.1 years average tenure).

Syros Pharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Insufficient new directors

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Insufficient new directors

Insufficient new directors

Insider recently bought US$106k worth of stock

Recent updates

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$5.81 loss per share (vs US$7.49 loss in FY 2022)

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Forecast to breakeven in 2026

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Insufficient new directors

Third quarter 2023 earnings released: US$1.43 loss per share (vs US$3.21 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Second quarter 2023 earnings released: US$1.30 loss per share (vs US$5.40 loss in 2Q 2022)

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings released: US$0.85 loss per share (vs US$3.99 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: US$7.49 loss per share (vs US$13.84 loss in FY 2021)

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Third quarter 2022 earnings released: US$3.21 loss per share (vs US$4.14 loss in 3Q 2021)

Insufficient new directors

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought US$106k worth of stock

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Insufficient new directors

Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.36 loss in 2Q 2021)

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

Insufficient new directors

First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.23 loss in 1Q 2021)

Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

Syros Pharmaceuticals Provides Update on its Clinical Development Programs and Outlined its Strategic Priorities and Upcoming Expected Milestones

Insufficient new directors

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.43 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

Syros Pharmaceuticals, Inc. Presents New Data from Phase 1 Trial of Sy-5609 and Details Three-Pronged Combination Strategy to Advance Sy-5609 in Solid Tumors and Blood Cancer

Syros Pharmaceuticals Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML

Second quarter 2021 earnings released: US$0.36 loss per share (vs US$0.38 loss in 2Q 2020)

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.39 loss in 1Q 2020)

Full year 2020 earnings released: US$1.83 loss per share (vs US$1.88 loss in FY 2019)

Revenue beats expectations

Syros Pharmaceuticals, Inc. announced that it has received $20 million in funding from Oxford Finance LLC

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age